LSTA
Lisata Therapeutics, Inc.
Price Chart
Latest Quote
$3.44
-0.03 (-0.86%)
Current Price
| Previous Close | $3.47 |
| Open | $3.49 |
| Day High | $3.50 |
| Day Low | $3.44 |
| Volume | 19,362 |
Stock Information
| Shares Outstanding | 9.11M |
| Cash Equivalents | $13.06M |
| Revenue | $170K |
| Net Income | $-16.35M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $31.33M |
| EPS (TTM) | $-1.86 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $18.01M |
| Sales | $170K |
| Income | $-16.35M |
| Book/sh | $1.20 |
| Cash/sh | $1.43 |
| Employees | 21 |
Financial Ratios
| Quick Ratio | 4.00 |
| Current Ratio | 4.23 |
Returns & Margins
| ROA | -50.26% |
| ROE | -91.41% |
| Gross Margin | 100.00% |
| Operating Margin | -10178.82% |
Ownership
| Insider Ownership | 20.89% |
| Institutional Ownership | 11.43% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.97 |
| PEG | 118.40 |
| P/S | 184.27 |
| P/B | 2.87 |
Analyst Data
| Recommendation | none |
| Target Price | $4.00 |
Technical Indicators
| SMA20 | $3.45 |
| SMA50 | $3.34 |
| SMA200 | $3.20 |
| RSI | 47.78 |
| ATR | 0.1450 |
| Shares Float | 7.20M |
| Short Float | 1.65% |
| Short Ratio | 3.07 |
| Volatility | 0.81 |
| Rel Volume | 0.09 |
Performance History
| Week | -1.43% |
| Month | +9.55% |
| Quarter | -31.47% |
| 6 Months | +66.99% |
| YTD | +75.51% |
| Year | +43.93% |
| 3 Years | -14.00% |
| 5 Years | -85.39% |
| 10 Years | -95.41% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $3.44 | 19,500 |
| 2026-06-23 | $3.47 | 12,300 |
| 2026-06-22 | $3.47 | 32,500 |
| 2026-06-18 | $3.52 | 41,500 |
| 2026-06-17 | $3.52 | 13,900 |
| 2026-06-16 | $3.49 | 13,800 |
| 2026-06-15 | $3.45 | 32,200 |
| 2026-06-12 | $3.56 | 56,300 |
| 2026-06-11 | $3.48 | 54,600 |
| 2026-06-10 | $3.61 | 867,000 |
| 2026-06-09 | $3.46 | 91,400 |
| 2026-06-08 | $3.48 | 35,500 |
| 2026-06-05 | $3.35 | 22,800 |
| 2026-06-04 | $3.37 | 97,200 |
| 2026-06-03 | $3.48 | 49,500 |
| 2026-06-02 | $3.48 | 160,500 |
| 2026-06-01 | $3.58 | 965,200 |
| 2026-05-29 | $3.25 | 1,763,200 |
| 2026-05-28 | $3.30 | 73,500 |
| 2026-05-27 | $3.30 | 79,500 |
| 2026-05-26 | $3.20 | 64,200 |
About Lisata Therapeutics, Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
đ° Latest News
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
Proactive âĸ 2026-06-10T13:36:00Z
Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances
Proactive âĸ 2026-03-09T14:29:00Z
Lisata Therapeutics And 2 Other Penny Stocks Worth Watching
Simply Wall St. âĸ 2026-01-22T12:04:49Z
How The Evolving Story For Lisata Therapeutics (LSTA) Is Reshaping Its Valuation Outlook
Simply Wall St. âĸ 2026-01-22T07:07:12Z
Lisata Therapeutics Inc (LSTA) Q3 2025 Earnings Call Highlights: Strategic Alliances and Cost ...
GuruFocus.com âĸ 2025-11-07T05:00:59Z
Lisata Therapeutics Partners with Catalent on ADC Technology
Exec Edge âĸ 2025-10-09T15:16:53Z
Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Invest In Growth?
Simply Wall St. âĸ 2025-10-03T15:52:29Z
Lisata Therapeutics Highlights Preliminary Data in Pancreatic Cancer Study
Exec Edge âĸ 2025-09-30T19:04:30Z
Lisata Secures New Composition of Matter Patent for Certepetide
Exec Edge âĸ 2025-07-17T18:58:32Z
Lisata Reports Survival, Response Benefits With Certepetide in Pancreatic Cancer Trial
MT Newswires âĸ 2025-06-26T15:58:12Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $170,000 | $1,000,000 | $0 | $0 |
| Operating Revenue | $170,000 | $1,000,000 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $18,379,000 | $23,409,000 | $25,708,000 | $57,601,000 |
| Other Income Expense | $661,000 | $1,626,000 | $2,538,000 | $897,000 |
| Other Non Operating Income Expenses | $-145,000 | $-257,000 | $-186,000 | $-155,000 |
| Operating Expense | $18,379,000 | $23,409,000 | $25,708,000 | $57,601,000 |
| General And Administrative Expense | $10,430,000 | $12,075,000 | $12,974,000 | $14,141,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-16,586,000 | $-19,985,000 | $-20,840,000 | $-54,225,000 |
| Normalized Income | $-17,347,814 | $-21,795,699 | $-23,290,072 | $-55,231,008 |
| Net Income From Continuing And Discontinued Operation | $-16,586,000 | $-19,985,000 | $-20,840,000 | $-54,225,000 |
| Total Operating Income As Reported | $-18,209,000 | $-22,409,000 | $-25,708,000 | $-57,601,000 |
| Net Income Common Stockholders | $-16,586,000 | $-19,985,000 | $-20,840,000 | $-54,225,000 |
| Net Income | $-16,586,000 | $-19,985,000 | $-20,840,000 | $-54,225,000 |
| Net Income Including Noncontrolling Interests | $-16,586,000 | $-19,985,000 | $-20,840,000 | $-54,225,000 |
| Net Income Continuous Operations | $-16,586,000 | $-19,985,000 | $-20,840,000 | $-54,225,000 |
| Pretax Income | $-17,548,000 | $-20,783,000 | $-23,170,000 | $-56,704,000 |
| Operating Income | $-18,209,000 | $-22,409,000 | $-25,708,000 | $-57,601,000 |
| Per Share | ||||
| Diluted EPS | $-1.91 | $-2.40 | $-2.58 | $-10.47 |
| Basic EPS | $-1.91 | $-2.40 | $-2.58 | $-10.47 |
| Other | ||||
| Tax Effect Of Unusual Items | $44,186 | $72,301 | $273,928 | $45,992 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-18,869,000 | $-24,118,000 | $-28,243,000 | $-58,584,000 |
| Total Unusual Items | $806,000 | $1,883,000 | $2,724,000 | $1,052,000 |
| Total Unusual Items Excluding Goodwill | $806,000 | $1,883,000 | $2,724,000 | $1,052,000 |
| Reconciled Depreciation | $146,000 | $174,000 | $189,000 | $69,000 |
| EBITDA (Bullshit earnings) | $-18,063,000 | $-22,235,000 | $-25,519,000 | $-57,532,000 |
| EBIT | $-18,209,000 | $-22,409,000 | $-25,708,000 | $-57,601,000 |
| Diluted Average Shares | $8,687,000 | $8,329,000 | $8,073,000 | $5,180,000 |
| Basic Average Shares | $8,687,000 | $8,329,000 | $8,073,000 | $5,180,000 |
| Diluted NI Availto Com Stockholders | $-16,586,000 | $-19,985,000 | $-20,840,000 | $-54,225,000 |
| Minority Interests | $0 | $0 | $0 | $0 |
| Tax Provision | $-962,000 | $-798,000 | $-2,330,000 | $-2,479,000 |
| Gain On Sale Of Security | $806,000 | $1,883,000 | $2,724,000 | $1,052,000 |
| Research And Development | $7,949,000 | $11,334,000 | $12,734,000 | $43,460,000 |
| Selling General And Administration | $10,430,000 | $12,075,000 | $12,974,000 | $14,141,000 |
| Other Gand A | $10,430,000 | $12,075,000 | $12,974,000 | $14,141,000 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $14,855,000 | $29,379,000 | $47,885,000 | $66,244,000 |
| Total Assets | $17,744,000 | $35,002,000 | $54,694,000 | $73,034,000 |
| Total Non Current Assets | $41,000 | $424,000 | $770,000 | $1,158,000 |
| Other Non Current Assets | $23,000 | $160,000 | $332,000 | $528,000 |
| Goodwill And Other Intangible Assets | $0 | $192,000 | $263,000 | $334,000 |
| Current Assets | $17,703,000 | $34,578,000 | $53,924,000 | $71,876,000 |
| Other Current Assets | $1,747,000 | $2,433,000 | $3,389,000 | $2,650,000 |
| Receivables | $0 | $900,000 | $0 | - |
| Accounts Receivable | $0 | $900,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $15,956,000 | $31,245,000 | $50,535,000 | $69,226,000 |
| Cash And Cash Equivalents | $15,956,000 | $16,209,000 | $22,593,000 | $32,154,000 |
| Other Intangible Assets | - | $192,000 | $263,000 | $334,000 |
| Cash Equivalents | - | - | $16,715,000 | $27,668,000 |
| Cash Financial | - | - | $5,878,000 | $4,486,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $0 | $137,000 | $168,000 | $180,000 |
| Current Debt And Capital Lease Obligation | - | $137,000 | $168,000 | $180,000 |
| Long Term Debt And Capital Lease Obligation | - | - | - | $305,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,143,000 | $5,685,000 | $6,800,000 | $6,710,000 |
| Total Non Current Liabilities Net Minority Interest | $72,000 | $72,000 | $210,000 | $327,000 |
| Other Non Current Liabilities | $72,000 | $72,000 | $210,000 | $327,000 |
| Current Liabilities | $3,071,000 | $5,613,000 | $6,590,000 | $6,383,000 |
| Payables And Accrued Expenses | $3,071,000 | $5,476,000 | $6,422,000 | $6,203,000 |
| Payables | $1,019,000 | $1,284,000 | $2,421,000 | $2,655,000 |
| Accounts Payable | $1,019,000 | $1,284,000 | $2,421,000 | $2,655,000 |
| Equity | ||||
| Common Stock Equity | $14,855,000 | $29,571,000 | $48,148,000 | $66,578,000 |
| Total Equity Gross Minority Interest | $14,601,000 | $29,317,000 | $47,894,000 | $66,324,000 |
| Stockholders Equity | $14,855,000 | $29,571,000 | $48,148,000 | $66,578,000 |
| Gains Losses Not Affecting Retained Earnings | $-37,000 | $-81,000 | $-42,000 | $-29,000 |
| Other Equity Adjustments | $-37,000 | $-81,000 | $-42,000 | $-29,000 |
| Retained Earnings | $-564,652,000 | $-548,066,000 | $-528,081,000 | $-507,241,000 |
| Other | ||||
| Treasury Shares Number | $738 | $738 | $738 | $738 |
| Ordinary Shares Number | $8,833,875 | $8,408,844 | $8,149,897 | $7,900,000 |
| Share Issued | $8,834,613 | $8,409,582 | $8,150,635 | $7,900,738 |
| Tangible Book Value | $14,855,000 | $29,379,000 | $47,885,000 | $66,244,000 |
| Invested Capital | $14,855,000 | $29,571,000 | $48,148,000 | $66,578,000 |
| Working Capital | $14,632,000 | $28,965,000 | $47,334,000 | $65,493,000 |
| Capital Lease Obligations | $0 | $137,000 | $168,000 | $180,000 |
| Total Capitalization | $14,855,000 | $29,571,000 | $48,148,000 | $66,578,000 |
| Minority Interest | $-254,000 | $-254,000 | $-254,000 | $-254,000 |
| Treasury Stock | $708,000 | $708,000 | $708,000 | $708,000 |
| Additional Paid In Capital | $580,243,000 | $578,418,000 | $576,971,000 | $574,548,000 |
| Capital Stock | $9,000 | $8,000 | $8,000 | $8,000 |
| Common Stock | $9,000 | $8,000 | $8,000 | $8,000 |
| Current Capital Lease Obligation | $0 | $137,000 | $168,000 | $180,000 |
| Current Accrued Expenses | $2,052,000 | $4,192,000 | $4,001,000 | $3,548,000 |
| Net PPE | $18,000 | $72,000 | $175,000 | $296,000 |
| Accumulated Depreciation | $-476,000 | $-589,000 | $-486,000 | $-417,000 |
| Gross PPE | $494,000 | $661,000 | $661,000 | $713,000 |
| Leases | $0 | $72,000 | $72,000 | $99,000 |
| Machinery Furniture Equipment | $494,000 | $589,000 | $589,000 | $614,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $0 | $15,036,000 | $27,942,000 | $37,072,000 |
| Preferred Stock | - | - | - | $0 |
| Long Term Capital Lease Obligation | - | - | - | $305,000 |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-15,977,000 | $-19,356,000 | $-20,032,000 | $-21,455,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-15,949,000 | $-19,356,000 | $-20,032,000 | $-21,170,000 |
| Cash Flow From Continuing Operating Activities | $-15,949,000 | $-19,356,000 | $-20,032,000 | $-21,170,000 |
| Operating Gains Losses | - | $130,000 | $3,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-28,000 | - | - | $-285,000 |
| Investing Cash Flow | $15,086,000 | $13,233,000 | $10,102,000 | $28,911,000 |
| Cash Flow From Continuing Investing Activities | $15,086,000 | $13,233,000 | $10,102,000 | $28,911,000 |
| Net Other Investing Changes | - | - | - | $-3,320,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $844,000 | $68,000 | $321,000 | $43,000 |
| Financing Cash Flow | $599,000 | $-206,000 | $385,000 | $-224,000 |
| Cash Flow From Continuing Financing Activities | $599,000 | $-206,000 | $385,000 | $-224,000 |
| Net Other Financing Charges | $-253,000 | $-274,000 | $-91,000 | $-267,000 |
| Net Common Stock Issuance | $844,000 | $68,000 | $321,000 | $43,000 |
| Common Stock Issuance | $844,000 | $68,000 | $321,000 | $43,000 |
| Other | ||||
| End Cash Position | $15,956,000 | $16,209,000 | $22,593,000 | $32,154,000 |
| Beginning Cash Position | $16,209,000 | $22,593,000 | $32,154,000 | $24,647,000 |
| Effect Of Exchange Rate Changes | $11,000 | $-55,000 | $-16,000 | $-10,000 |
| Changes In Cash | $-264,000 | $-6,329,000 | $-9,545,000 | $7,517,000 |
| Proceeds From Stock Option Exercised | $8,000 | $0 | $155,000 | $0 |
| Net Investment Purchase And Sale | $15,114,000 | $13,363,000 | $10,102,000 | $32,516,000 |
| Sale Of Investment | $24,294,000 | $69,051,000 | $108,581,000 | $122,203,000 |
| Purchase Of Investment | $-9,180,000 | $-55,688,000 | $-98,479,000 | $-89,687,000 |
| Net Business Purchase And Sale | $0 | $-130,000 | $0 | - |
| Purchase Of Business | $0 | $-130,000 | $0 | - |
| Net PPE Purchase And Sale | $-28,000 | $0 | $0 | $-285,000 |
| Purchase Of PPE | $-28,000 | $0 | $0 | $-285,000 |
| Change In Working Capital | $-1,287,000 | $-873,000 | $-462,000 | $-831,000 |
| Change In Other Current Assets | $140,000 | $170,000 | $274,000 | $237,000 |
| Change In Payables And Accrued Expense | $-2,570,000 | $-995,000 | $88,000 | $-223,000 |
| Change In Payable | $-2,570,000 | $-995,000 | $88,000 | - |
| Change In Account Payable | $-2,570,000 | $-995,000 | $88,000 | - |
| Change In Prepaid Assets | $742,000 | $852,000 | $-824,000 | $-845,000 |
| Change In Receivables | $401,000 | $-900,000 | $0 | - |
| Changes In Account Receivables | $401,000 | $-900,000 | $0 | - |
| Stock Based Compensation | $1,226,000 | $1,653,000 | $2,038,000 | $2,636,000 |
| Provisionand Write Offof Assets | $500,000 | $0 | - | - |
| Asset Impairment Charge | $127,000 | $0 | - | - |
| Amortization Of Securities | $-75,000 | $-455,000 | $-960,000 | $788,000 |
| Depreciation Amortization Depletion | $146,000 | $174,000 | $189,000 | $69,000 |
| Depreciation And Amortization | $146,000 | $174,000 | $189,000 | $69,000 |
| Earnings Losses From Equity Investments | $0 | $130,000 | $0 | - |
| Net Income From Continuing Operations | $-16,586,000 | $-19,985,000 | $-20,840,000 | $-54,225,000 |
| Gain Loss On Sale Of PPE | - | $0 | $3,000 | $0 |
| Other Non Cash Items | - | - | - | $30,393,000 |
| Interest Paid Supplemental Data | - | - | - | - |
| Income Tax Paid Supplemental Data | - | - | - | - |
Fetched: 2026-06-23